Incyte Corporation Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Best And Worst Performing Nasdaq 100 Stocks Of 2018
Article By: Bespoke Investment Group
Friday, May 25, 2018 1:49 PM EDT
The average stock in the Nasdaq 100 is up just over 3% year-to-date. Here is a look at the best and worst performing stocks in the Nasdaq 100 so far in 2018.
In this article: ALGN, ADBE, ADSK, AMZN, INTC, MSFT, MU, NFLX, NVDA, STX, WYNN, INCY, CELG, CMCSA, DISH, NTES, SYMC, XRAY, KHC
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA
Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Goldman Sachs: These 5 Stocks Can Break Higher
Article By: TipRanks
Sunday, April 22, 2018 12:29 PM EDT
With the market in gridlock, Goldman Sachs has identified 14 stocks that seem to offer big upside potential.
In this article: NBL, NFX, ALXN, INCY, AVGO
Read
Incyte Upgraded To Buy From Neutral At UBS
Article By: The Fly
Thursday, April 12, 2018 7:56 AM EDT
UBS analyst Carter Gould upgraded Incyte to Buy while lowering his price target for the shares to $76 from $106.
In this article: INCY
Read
Get Rid Of 5 Toxic Stocks Or Sell Short For Profit
Article By: Zacks Investment Research
Monday, February 19, 2018 10:20 PM EDT
Accurate identification of overhyped toxic stocks and the rightly priced ones is very important for investing success. However, correctly figuring out toxic stocks and removing them at the right time to make some profits is not easy.
In this article: LYV, PTC, AROC, ATUS, INCY
Read

PARTNER HEADLINES

Latest Tweets for $INCY

No tweets yet!